Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines

20th July 2017 Uncategorised 0

The latest immuno-oncology market-share numbers are out, and they show that Merck & Co.’s Keytruda is not only gaining on Bristol-Myers Squibb archrival Opdivo, but it’s picked up the pace, too. But Roche’s newer entrant, Tecentriq, hasn’t broken out of the single digits.

More: Merck's Keytruda speeds its I-O market-share grab as Bristol-Myers' Opdivo declines
Source: fierce